

IDEA2 Kickoff Workshop

John Priatel, PhD – Founder June 20-21st, 2019


DEDICATED TEAM

Proven expertise in cancer immunology



Salim Dhanji, PhD CEO and Founder

Formerly Director of Preclinical Research at Qu Biologics Inc. with 10 years of industry experience. Postdoctoral fellowship at the Princess Margaret Cancer Hospital Expertise in lymphocyte biology, cancer, and autoimmunity



Ken Harder, PhD Founder

Professor, Department of Microbiology and Immunology, UBC. Canada Research Chair Tier II in Host Pathogen/Tumour Immunology Expertise in cancer, biochemistry, hematopoiesis, and innate immunity



John Priatel, PhD Founder

Assistant Professor, Department of Pathology and Laboratory Medicine. UBC Staff Scientist, BC Children's Hospital Research Institute. Expertise in T cell biology of infection, autoimmunity, and cancer Founders have over 80 scientific publications and patents and >\$2 million in funded research

CURING CANCER

The promise of cancer immunotherapy

- Immuno-Oncology (IO) or cancer immunotherapy major area of cancer research
 - Market expected to reach **\$120B** by 2021 (Markets and Markets)
 - All large pharma companies have 1st gen IO programs
- Most important class of 1st gen IO drugs called **checkpoint inhibitors** turn off the "brakes" in cancer killing T cells
 - Durable responses in several cancers but only in a subset of patients
 - Other suppressive pathways still engaged
- How do we improve the response rate?
- Develop 2nd gen IO drugs targeting other pathways that can synergize with checkpoint inhibitors to increase response rate

SOLUTION

Overcome resistance – boost activity



Humanized antibody targeting G-CSF

- ME Therapeutics founded with goal of developing next generation IO treatments
- Research focused on myeloid cells which play a major role in resistance to first generation IO drugs
- Developed humanized therapeutic antibody against key driver of myeloid cell immune suppression
- Target G-CSF
- Goal inhibit G-CSF for a stronger anti-tumour immune responses

WHY TARGET G-CSF?

Multifaceted role of G-CSF in immune suppression

- G-CSF:
 - Strongly associated with poor survival in lung, breast, and colon cancer
 - Induces suppression of cancer killing T cells
 - Promotes metastases
 - Resistance to targeted cancer therapies (VEGF inhibitors)
- Activates several key cancer resistance pathways at once
- G-CSF inhibition can potentially remove multiple barriers to the success of current cancer therapy with one drug

THERAPEUTIC and IP

Humanized G-CSF blocking antibody

Therapeutic = humanized, high affinity anti-human G-CSF antibody \rightarrow ME1B11

- Ready for manufacture
- Provisional patent filed in 2017 (composition and use) on 2 lead antibodies (PCT filed 2018)
- IP 100% owned by ME Therapeutics
- Freedom to operate

SAFETY and EFFICACY

G-CSF can safely be blocked without undesired consequences

- G-CSF inhibition in vivo can **safely normalize** the effects of G-CSF on granulocytes in the blood
- Treatment does not cause neutropenia (on target side effect) even with 100% removal of detectable G-CSF
- Treatment safely and effectively blocks the effect of tumour-induced G-CSF on immune cells
- Reduces cancer growth and metastases in vivo and reduces immune suppression in the tumour
- Targeting the G-CSF pathway shown to be **safe in the clinic**
- Safety of therapy **easily monitored** with existing blood tests and any potential toxicity can be overcome with available drugs

MARKETS

Blockbuster potential

- IO drugs target immune system and not tumour directly
 - Many potential indications
- Our leads: Lung and colorectal cancer
- Lung cancer is responsive to IO but low response rate
 - Largest potential market
- Colorectal cancer under-served by IO but G-CSF likely plays significant role in resistance to current treatments
- Either market has blockbuster potential

Lung cancer

234,000 new cases annually (US)Annual immunotherapy cost\$150,000Assume 5% of patients treatable\$1.8 billion in annual revenue

Colorectal cancer

140,000 new cases annually (US)Annual immunotherapy cost\$150,000Assume 5% of patients treatable\$1.1 billion in annual revenue



What makes us unique



Founded in September 2014

6 PhDs on team (3 scientists and 3 founders) Raised \$860,000 CAD to date (\$380,000 dilutive)

Own 100% of our intellectual property

CONTACT

Salim Dhanji, PhD CEO and founder

Address

3540 – 2350 Health Sciences Mall Vancouver, BC, Canada V6T 1Z3

🔀 Contact Info

Email: salim@metherapeutics.com

